Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AX 9115

Next Previous
Drug Profile

AX 9115

Alternative Names: AX-9115

Latest Information Update: 25 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProQR Therapeutics
  • Class Oligonucleotides
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Metabolic disorders

Most Recent Events

  • 18 Apr 2023 ProQR Therapeutics has patent protection for Axiomer® platform in China, Canada, Israel, New Zealand, Japan, Russia, South Africa, the US and Europe
  • 05 Apr 2023 Early research in Metabolic disorders in Netherlands (Parenteral)
  • 31 Dec 2022 ProQR Therapeutics has patent pending for Axiomer® platform in Australia, Brazil, India, and the US (divisional application)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top